December 20, 2017 / 9:07 PM / 8 months ago

BRIEF-FDA Approves Genentech's Perjeta For Post Surgery Treatment Of A Type Of Breast Cancer

Dec 20 (Reuters) - Roche Holding Ag:

* FDA APPROVES GENENTECH’S PERJETA (PERTUZUMAB) FOR ADJUVANT TREATMENT OF SPECIFIC TYPE OF EARLY BREAST CANCER

* GENENTECH- ‍FDA CONVERTED PREVIOUSLY GRANTED ACCELERATED APPROVAL OF PERJETA-BASED REGIMEN TO FULL APPROVAL FOR NEOADJUVANT TREATMENT OF HER2-POSITIVE​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below